Although there appears to be a strong association between Gd exposure and NSF, potential triggers are still being evaluated. In the past decade, there has been a dramatic shift to the use of MRA with Gd contrast in patients with renal failure due to known contrast-induced nephropathy observed with iodinated contrast. Considering the number of patients with renal failure receiving Gd contrast, Gd exposure alone is unlikely to be the sole cause of NSF and is more likely a component in a multifactorial process; however, the other risk factors remain elusive. MRA technology has been lifesaving for many patients with renal failure and remains a medical necessity in many situations, but the possible link to NSF may result in a need to modify current medical practices. The FDA's public health advisory strongly recommends prompt initiation of dialysis in any patient with advanced kidney disease who undergoes MRA with Gd.16 With the potential association of the dissociation of Gd chelates in an acidic environment, it also may be prudent to consider normalizing the pH of patients with bicarbonate infusion prior to MRA. At this time, further studies evaluating the safety of Gd contrast, its possible link to NSF, and the possible role of macrophage inhibition in the pathophysiology of NSF are needed.
Article
Nephrogenic Systemic Fibrosis: Is Gadolinium the Missing Piece to the Puzzle? (See Erratum 2008;82:158)
Cutis. 2008 May;81(5):421-426
Author and Disclosure Information
Drs. Bennett and Garrett report no conflict of interest. The authors discuss the off-label use of gadolinium-based contrast agents for magnetic resonance angiography. Dr. Bennett is a resident, Departments of Dermatology and Internal Medicine, University of Wisconsin, Madison. Dr. Garrett is a dermatologist, Department of Dermatology, Dean Health System, Madison.
Lindsey K. Bennett, MD; Andrea L. Garrett, MD